Smith Optics and Koroyd have jointly filed a patent infringement action against Burton, claiming that the WaveCel shock-absorbing material Burton uses in some helmets infringes on their jointly owned patent.
The suit against Burton in the United States District Court for the District of Utah accusing Burton of infringing US Patent No.10,736, 373 (jointly owned by Smith & Koroyd) by selling and importing Anon-branded Logan and Merak snow helmets that incorporate WaveCel technology.
According to the lawsuit, Burton was informed of Smith’s and Koroyd’s patent rights, and was asked to respect those rights by not making or selling the accused Anon-branded Wavecel helmets. Burton moved forward with the launch of the Anon helmets, leaving Smith and Koroyd no choice but to pursue the federal court action to protect their intellectual property rights. A second lawsuit brought by Koroyd against Burton in Germany also alleges IP violations based on WaveCel® helmets.
Share:
NEW YORK, July 15, 2021 (GLOBE NEWSWIRE) Pomerantz LLP announces that a class action lawsuit has been filed against Frequency Therapeutics, Inc. ( Frequency or the Company ) (NASDAQ:FREQ) and certain of its officers. The class action, filed in the United States District Court for the District of Massachusetts, and docketed under 21-cv-11040, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Frequency s common stock between November 16, 2020 and March 22, 2021, inclusive (the Class Period ), seeking to pursue remedies under the Securities Exchange Act of 1934 (the Exchange Act ). This action brings claims against Defendants Frequency and the Company s Chief Executive Officer ( CEO ), David L. Lucchino ( Lucchino ), and seeks to recover damages caused by Defendants violations of the Exchange Act.
Intellipharmaceutics Announces Second Quarter 2021 Results
ACCESSWIRE
16 Jul 2021, 06:55 GMT+10
TORONTO, ON / ACCESSWIRE / July 15, 2021 / Intellipharmaceutics International Inc. (OTCQB:IPCIF)(TSX:IPCI) ( Intellipharmaceutics or the Company ), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today reported the results of operations for the three and six months ended May 31, 2021. All dollar amounts referenced herein are in United States dollars unless otherwise noted.
Effective May 5, 2021 our exclusive license agreements with Tris Pharma, Inc. for generic Seroquel XR®, generic Pristiq® and generic Effexor XR® were mutually terminated. Products were never supplied nor distributed under the licenses. Termination of the exclusive agreements may provide opportunity for the Company to explore options of supplying the products to multiple sources on non-exclusiv
Share:
WEST FARGO, N.D., July 15, 2021 /PRNewswire-PRWeb/ Attorney David Chapman announced today he has commenced a lawsuit in the United States District Court for the District of Minnesota on behalf of his clients Ray and Kathie Kvalvog. The lawsuit against the Minnesota State Patrol, Park Christian School, former Park Christian School head varsity basketball coach Josh Lee and former head football coach Tim Kerr is for the alleged denial of the Kvalvog s civil rights in the alleged connection with the civil suit regarding a 2015 crash that claimed the lives of their sons, Zachary and Connor Kvalvog.
The lawsuit alleges Eischens wrote a report in a fashion that deflected attention from his friends at Park Christian School. The suit alleges that because Sgt. Eischens had close ties with the top leaders of the school it was his desire to protect his close family friends.
Home / Top News / ATHA Deadline Alert: Kessler Topaz Meltzer & Check, LLP Reminds Investors of August 24, 2021 Deadline in Securities Fraud Class Action Lawsuit
ATHA Deadline Alert: Kessler Topaz Meltzer & Check, LLP Reminds Investors of August 24, 2021 Deadline in Securities Fraud Class Action Lawsuit
RADNOR, Pa., July 15, 2021 (GLOBE NEWSWIRE) The law firm of Kessler Topaz Meltzer & Check, LLP announces that securities fraud class action lawsuits have been filed in the United States District Court for the Western District of Washington against Athira Pharma, Inc. (NASDAQ: ATHA) (“Athira”) on behalf of those who purchased or acquired Athira common stock:
a) pursuant and/or traceable to the registration statement and prospectus (collectively, the “Registration Statement”) issued in connection with Athira’s September 2020 initial public offering (“IPO”); and/or b) between September 18, 2020 and June 17, 2021, inclusive (the “Class Period”).